Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity of hIL-11 (1.50 ng/mL), a concentration of 0.02 - 0.05 μ,g/mL of this antibody is required.
ELISA:
To detect hIL-11 by direct ELISA (using 100 μ,L/well antibody solution) a concentration of at least 0.5 μ,g/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant hIL-11.
Sandwich:
To detect hIL-11 by sandwich ELISA (using 100 μ,L/well antibody solution) a concentration of 0.5 - 2.0 μ,g/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with our Biotinylated Anti-Human IL-11 (XP-5164Bt) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIL-11.
Western Blot: To detect hIL-11 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μ,g/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-11 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Restrictions
For Research Use only
Format
Lyophilized
Storage
-20 °C
Storage Comment
IL-11 antibody is stable for at least 2 years from date of receipt at -20°C. The reconstituted antibody is stable for at least two weeks at 2-8°C. Frozen aliquots are stable for at least 6 months when stored at -20°C. Avoid repeated freeze-thaw cycles.
Interleukin 11 is a pleiotropic cytokine produced by mesenchymal-derived adherent cells. IL11 shares many functions of IL6 and LIF, including potentiation of megakaryocyte activity, enhancement of human myeloma cell proliferation, and enhancement of hepatic acute phase protein production. Interleukin 11 directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, and induces megakaryocyte maturation resulting in increased platelet production. Clinically it is used to prevent severe thrombocytopenia and the reduction of the need for platelet transfusion following myelosuppressive chemotherapy.